PL2621494T3 - Zastosowanie stearynianu magnezu w preparatach w postaci suchego proszku do inhalacji - Google Patents

Zastosowanie stearynianu magnezu w preparatach w postaci suchego proszku do inhalacji

Info

Publication number
PL2621494T3
PL2621494T3 PL11767661T PL11767661T PL2621494T3 PL 2621494 T3 PL2621494 T3 PL 2621494T3 PL 11767661 T PL11767661 T PL 11767661T PL 11767661 T PL11767661 T PL 11767661T PL 2621494 T3 PL2621494 T3 PL 2621494T3
Authority
PL
Poland
Prior art keywords
inhalation
magnesium stearate
dry powder
powder formulations
formulations
Prior art date
Application number
PL11767661T
Other languages
English (en)
Inventor
Daniela Cocconi
Massimiliano Dagli Alberi
Andrea Busca
Francesca Schiaretti
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of PL2621494T3 publication Critical patent/PL2621494T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11767661T 2010-09-30 2011-09-16 Zastosowanie stearynianu magnezu w preparatach w postaci suchego proszku do inhalacji PL2621494T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10183018 2010-09-30
PCT/EP2011/066062 WO2012041717A1 (en) 2010-09-30 2011-09-16 Use of magnesium stearate in dry powder formulations for inhalation
EP11767661.9A EP2621494B1 (en) 2010-09-30 2011-09-16 Use of magnesium stearate in dry powder formulations for inhalation

Publications (1)

Publication Number Publication Date
PL2621494T3 true PL2621494T3 (pl) 2019-04-30

Family

ID=43618674

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11767661T PL2621494T3 (pl) 2010-09-30 2011-09-16 Zastosowanie stearynianu magnezu w preparatach w postaci suchego proszku do inhalacji

Country Status (12)

Country Link
US (3) US20120082727A1 (pl)
EP (1) EP2621494B1 (pl)
KR (2) KR20140005150A (pl)
CN (1) CN103298470B (pl)
AR (1) AR083208A1 (pl)
BR (1) BR112013007022B1 (pl)
CA (1) CA2813096C (pl)
ES (1) ES2704688T3 (pl)
PL (1) PL2621494T3 (pl)
RU (1) RU2580890C2 (pl)
TR (1) TR201901644T4 (pl)
WO (1) WO2012041717A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2011120779A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
NZ627963A (en) 2012-03-13 2015-08-28 Respivert Ltd Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase
KR20140147891A (ko) 2012-04-13 2014-12-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 응집체 입자
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
WO2014106727A1 (en) * 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) * 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
CN111565711B (zh) 2017-07-20 2023-01-03 阿茨治疗股份有限公司 色甘酸钠和布洛芬的粉末化制剂
CA3076353A1 (en) * 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
CN116617402A (zh) * 2022-02-10 2023-08-22 北京新领先医药科技发展有限公司 一种降低药物中美拉德反应的制备方法
WO2023224577A1 (en) * 2022-05-18 2023-11-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising micronized human insulin

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1150895C (zh) * 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
PT1158958E (pt) 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
PT1386630E (pt) 2002-07-31 2006-09-29 Chiesi Farma Spa Inalador em po
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
JP2009513529A (ja) 2003-07-11 2009-04-02 グラクソ グループ リミテッド ステアリン酸マグネシウムを含む医薬製剤
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0714134D0 (en) * 2007-07-19 2007-08-29 Norton Healthcare Ltd Dry-powder medicament
US7590021B2 (en) 2007-07-26 2009-09-15 Qualcomm Incorporated System and method to reduce dynamic RAM power consumption via the use of valid data indicators
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof

Also Published As

Publication number Publication date
AR083208A1 (es) 2013-02-06
KR101886987B1 (ko) 2018-08-08
HK1187822A1 (en) 2014-04-17
WO2012041717A1 (en) 2012-04-05
CN103298470B (zh) 2015-06-17
ES2704688T3 (es) 2019-03-19
US20150320691A1 (en) 2015-11-12
TR201901644T4 (tr) 2019-02-21
RU2580890C2 (ru) 2016-04-10
EP2621494A1 (en) 2013-08-07
US20180133161A1 (en) 2018-05-17
CA2813096C (en) 2019-10-29
CN103298470A (zh) 2013-09-11
BR112013007022B1 (pt) 2019-10-15
EP2621494B1 (en) 2018-11-07
BR112013007022A2 (pt) 2016-06-14
CA2813096A1 (en) 2012-04-05
KR20170118231A (ko) 2017-10-24
KR20140005150A (ko) 2014-01-14
US20120082727A1 (en) 2012-04-05
RU2013113965A (ru) 2014-10-10

Similar Documents

Publication Publication Date Title
AU334296S (en) Dry powder inhaler
AU334256S (en) Dry powder inhaler
AU334237S (en) Dry powder inhaler
AU334238S (en) Dry powder inhaler
EP2362796A4 (en) dry powder inhaler
EP2432535A4 (en) dry powder inhalers
PL2616064T3 (pl) Gotowe do zastosowania formulacje ketorolaku
EP2621588A4 (en) METHODS AND COMPOSITIONS FOR TREATING DISEASE USING INHALATION
EP2563372A4 (en) PREBIOTIC FORMULATIONS AND USE METHOD THEREFOR
IL216294A0 (en) Dry powder inhaler
IL216292A0 (en) Dry powder inhaler
PH12013500082A1 (en) Formulations of rifaximin and uses thereof
ZA201403422B (en) Dry powder formulation of azole derivative for inhalation
HRP20260101T1 (hr) Terapijski agens koji inducira citotoksičnost
IL216293A0 (en) Dry powder inhaler
ZA201207634B (en) Pharmaceutical powder composition for inhalation
SG11201400918TA (en) Compositions for skin exfoliation and use thereof
IL221043A0 (en) Modified release formulation and methods of use
PL2558148T3 (pl) Przycisk ustnika inhalatora suchego proszku
PT3613421T (pt) Ácido acetilsalicílico para reduzir o risco de um evento tromboembólico
IL213737A0 (en) Dry powder pharmaceutical compositions for inhalation and uses thereof
ZA201302952B (en) Fungicidal compositions and methods of use
PL2729207T3 (pl) Inhalator suchego proszku
AU333960S (en) Dose disk for dry powder inhaler
GB0912373D0 (en) Improvements in or relating to dry powder inhalers